Tenax Therapeutics (TENX)

$7.10 +0.41 (6.13%)
Market Cap 31.89M
Revenue (ttm) 0.00
Net Income (ttm) -17.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 153,111
Avg Vol 95,848
Day's Range N/A - N/A
Shares Out 4.56M
Stochastic %K 19%
Beta 1.52
Analysts Strong Sell
Price Target $21.00

Company Profile

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was former...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 855 2100
Address:
101 Glen Lennox Drive, Suite 300, Chapel Hill, United States
FE123
FE123 Nov. 14 at 9:31 PM
$IOVA $CDTX $TENX Steve Cohen’s next $200 Company $TENX Look at all the Buying!! 108% Only 4.5 Million Shares!!
0 · Reply
FE123
FE123 Nov. 14 at 9:25 PM
$TENX Another Buyer! 2 Tonight!!
0 · Reply
FE123
FE123 Nov. 14 at 9:21 PM
$TENX 108% Ownership!! Only 4.5 Million Shares!! Phase3!! Squeeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 9:18 PM
$NVDA $PLTR $TENX Institutions and Steve Cohen loading up!!
0 · Reply
FE123
FE123 Nov. 14 at 9:14 PM
$TENX WOW More Buying!!!
0 · Reply
FE123
FE123 Nov. 14 at 6:54 PM
$APLD $PALI $TENX lets Go!!
0 · Reply
FE123
FE123 Nov. 14 at 6:53 PM
$IOVA $PALI $TENX Squeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 6:36 PM
$TENX $PRAX $CDTX Bring those Profits to $TENX!!
0 · Reply
FE123
FE123 Nov. 14 at 6:32 PM
$NVDA $PLTR $TENX Steve Cohen wants the Squeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 3:51 PM
$PRAX $CDTX Bring those Profits to Steve Cohens $TENX only 4.5 Million Shares! 106% Ownership!! Phase3 $TENX Next t $200
0 · Reply
Latest News on TENX
Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript

Nov 13, 2025, 9:31 PM EST - 20 hours ago

Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 2 days ago

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Nov 6, 2025, 7:00 AM EST - 8 days ago

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:00 AM EST - 11 days ago

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Sep 16, 2025, 7:00 AM EDT - 2 months ago

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 6 months ago

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

Apr 16, 2025, 4:29 PM EDT - 7 months ago

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 4:05 PM EDT - 8 months ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:47 AM EST - 9 months ago

Tenax Therapeutics Announces $25 Million Private Placement

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 5, 2025, 8:42 AM EST - 9 months ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 9 months ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 9:00 AM EST - 10 months ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)

Nov 15, 2024, 11:47 AM EST - 1 year ago

Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

Aug 6, 2024, 7:13 AM EDT - 1 year ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 29, 2024, 9:00 AM EST - 1 year ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 20, 2024, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 8, 2024, 8:16 AM EST - 1 year ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 7, 2024, 8:01 PM EST - 1 year ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 10:01 AM EST - 1 year ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces Reverse Stock Split

Dec 29, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Reverse Stock Split

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Nov 17, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Jul 19, 2023, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023, 8:54 AM EDT - 2 years ago

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Provides 2023 Business Update

Apr 12, 2023, 8:45 AM EDT - 2 years ago

Tenax Therapeutics Provides 2023 Business Update

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 22, 2023, 8:45 AM EDT - 2 years ago

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Feb 3, 2023, 8:19 AM EST - 3 years ago

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Feb 1, 2023, 4:31 PM EST - 3 years ago

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Oct 10, 2022, 8:30 AM EDT - 3 years ago

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

Sep 15, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 23, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 18, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Mar 31, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Mar 30, 2022, 5:00 PM EDT - 3 years ago

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Jan 31, 2022, 4:10 PM EST - 4 years ago

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Jan 12, 2022, 8:30 AM EST - 4 years ago

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Jan 4, 2022, 8:30 AM EST - 4 years ago

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

Nov 16, 2021, 8:30 AM EST - 4 years ago

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

Oct 6, 2021, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

FE123
FE123 Nov. 14 at 9:31 PM
$IOVA $CDTX $TENX Steve Cohen’s next $200 Company $TENX Look at all the Buying!! 108% Only 4.5 Million Shares!!
0 · Reply
FE123
FE123 Nov. 14 at 9:25 PM
$TENX Another Buyer! 2 Tonight!!
0 · Reply
FE123
FE123 Nov. 14 at 9:21 PM
$TENX 108% Ownership!! Only 4.5 Million Shares!! Phase3!! Squeeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 9:18 PM
$NVDA $PLTR $TENX Institutions and Steve Cohen loading up!!
0 · Reply
FE123
FE123 Nov. 14 at 9:14 PM
$TENX WOW More Buying!!!
0 · Reply
FE123
FE123 Nov. 14 at 6:54 PM
$APLD $PALI $TENX lets Go!!
0 · Reply
FE123
FE123 Nov. 14 at 6:53 PM
$IOVA $PALI $TENX Squeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 6:36 PM
$TENX $PRAX $CDTX Bring those Profits to $TENX!!
0 · Reply
FE123
FE123 Nov. 14 at 6:32 PM
$NVDA $PLTR $TENX Steve Cohen wants the Squeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 3:51 PM
$PRAX $CDTX Bring those Profits to Steve Cohens $TENX only 4.5 Million Shares! 106% Ownership!! Phase3 $TENX Next t $200
0 · Reply
FE123
FE123 Nov. 14 at 2:40 PM
$CDTX Steve Cohen wants $200 for $TENX
0 · Reply
FE123
FE123 Nov. 14 at 2:38 PM
$NVDA $PLTR Steve Cohen Loves $TENX!!
0 · Reply
FE123
FE123 Nov. 14 at 2:28 PM
$TENX 10X from here is only 300 Million Market Cap!!
1 · Reply
FE123
FE123 Nov. 14 at 2:03 PM
$TENX Phase3 Company with Only 4.5 Million Shares and 106% Ownership!! Life Altering Medicine for 4 Million People!!
0 · Reply
FE123
FE123 Nov. 14 at 2:01 PM
$PRAX $CDTX Huge Winners for Steve Cohen! Now he loves $TENX!! Squeeeeze!!
0 · Reply
FE123
FE123 Nov. 14 at 12:24 PM
$NVDA $PLTR $TENX Steve Cohen!!
0 · Reply
FE123
FE123 Nov. 14 at 12:01 PM
$CDTX $AVDL M&A Going Strong!! Next $TENX $IOVA
0 · Reply
FE123
FE123 Nov. 14 at 10:47 AM
$PRAX $CDTX $TENX Steve Cohen!
0 · Reply
FE123
FE123 Nov. 14 at 10:17 AM
$CDTX $PRAX Steve Cohen loaded up Now he is loading up $TENX for $200
0 · Reply
FE123
FE123 Nov. 14 at 10:10 AM
$CDTX next is $TENX $IOVA
0 · Reply
FE123
FE123 Nov. 13 at 11:48 PM
$TENX Steve Cohen snd Venrock want another $CDTX
0 · Reply
FE123
FE123 Nov. 13 at 11:30 PM
$TENX Will be First Approved life altering Medicine!! as per Conference!!
0 · Reply